Damora Therapeutics, Inc.
NASDAQ:DMRABiotechnology
+$0.07 today
- Market cap
- $1.42B
- Beta
- 1.48
- P/E (TTM)
- -0.1
- EPS (TTM)
- -$177.15
Volume 0.58M
Average 0.33M
DMRA Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Damora Therapeutics, Inc.NASDAQ: DMRA
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization growth accelerates
Q1 FY2026 depreciation & amortization of $68K rose 750.0% year over year, ahead of the -37.3% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 871.4% from the prior quarter. Over 3 fiscal years it compounded at -58.9% a year.
Context
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +750.0% holds above the trailing-twelve-month pace of -37.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 34K USD
- Year-over-year change
- -81.2%
- 4-year CAGR
- -47.3%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 34K | -81.2% |
| FY2024 | 2024-12-31 | 181K | -78.2% |
| FY2023 | 2023-12-31 | 830K | +69.4% |
| FY2022 | 2022-12-31 | 490K | +11.1% |
| FY2021 | 2021-12-31 | 441K | — |
Depreciation & Amortization vs competitors
How DMRA compares with its peers on the latest reported figures
- DMRA's LTM Mar 2026 depreciation & amortization of $94K is the lowest of the 9 companies compared; the peer median is $1.99M.
- Its year-over-year change of -37.3% is the lowest of 7, against a peer median of +3.8%.
- Over three fiscal years its annual growth of -58.9% compares with a peer median of +20.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $98.28M | +8.6% | +11.2% | 1.7% | |
| LTM Jun 2026 | $44M | — | -41.9% | 1.1% | |
| LTM Mar 2026 | $13.19M | -9.3% | +20.0% | 72.9% | |
| LTM Mar 2026 | $2.41M | -1.0% | +34.3% | 0.8% | |
| LTM Mar 2026 | $1.57M | +21.0% | +30.8% | 4.7% | |
| LTM Mar 2026 | $1.04M | -17.2% | +11.5% | 0.5% | |
IRONDisc Medicine, Inc. | LTM Sep 2026 | $358K | +78.1% | +46.7% | — |
COAGHemab Therapeutics Holdings, Inc. Common Stock | FY2025 | $304K | — | — | — |
DMRADamora Therapeutics, Inc. | LTM Mar 2026 | $94K | -37.3% | -58.9% | — |
| Peer median (excluding DMRA) | $1.99M | +3.8% | +20.0% | 1.4% | |
Competitors are the stored peer set for DMRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 441K | 490K | 830K | 181K | 0 |
| Gross Profit | (441K) | (490K) | (830K) | (181K) | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 38.49M | 48.21M | 23.77M | 6.4M | 201.19M |
| Selling, General & Admin | 13.3M | 12.51M | 11.86M | 10.32M | 9.69M |
| Operating Expenses | 51.79M | 60.72M | 35.63M | 16.72M | 210.87M |
| Depreciation & Amortization | 441K | 490K | 830K | 181K | 34K |
| EBITDA | (51.31M) | (61.13M) | (37.52M) | (21.22M) | (209.76M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (52.23M) | (61.21M) | (36.46M) | (16.9M) | (210.87M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 156K | 722K | 1.69M | 844K | 1.17M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 475K | (417K) | (1.89M) | (4.5M) | 1.08M |
| Income Before Tax | (51.75M) | (61.62M) | (38.35M) | (21.4M) | (209.79M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 41K | 50K |
| Net Income | (51.75M) | (61.62M) | (38.35M) | (21.44M) | (209.84M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (51.22) | (60.63) | (36.08) | (18.53) | (158.13) |
| EPS (Diluted) | (51.22) | (60.63) | (36.08) | (18.53) | (158.13) |
| Weighted Avg Shares | 1.01M | 1.02M | 1.06M | 1.16M | 1.33M |
| Weighted Avg Shares (Diluted) | 1.01M | 1.02M | 1.06M | 1.16M | 1.33M |
Damora Therapeutics, Inc.
NASDAQ:DMRA
Intrinsic Alpha fair value
Locked
Current Price
$22.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.